Table 3. Overall seroprevalence of IgG antibodies to SARS-CoV-2 on point-of-care testing by participant characteristics
Maccura test negative, valid participants, n Maccura test positive, valid participants, n Diagreat test negative, valid participants, n Diagreat test positive, valid participants, n Seroprevalence estimate via Maccura, %Seroprevalence estimate via Maccura, 95% CISeroprevalence estimate via Diagreat, %Seroprevalence estimate via Diagreat, 95% CI
Overall8689981210612.37.4 to to 14.7
Female518594846212.37.1 to to 15.9
Male350403284412.3 6.6 to 17.74.3 0.0 to 14.8
Age, years
18–34143221182616.89.1 to to 12.8
35–4921220199209.93.8 to to 17.1
50–64256432474218.311.8 to to 20.3
≥6525714248185.00.0 to to 9.2
Participant type
Patient713836748812.67.5 to to 14.8
Healthcare worker155161381811.14.2 to to 17.3
Administration3213112.50.0 to to 10.6
Nursing44741817.65.9 to 33.810.70.0 to 30.6
Doctor36435412.31.5 to to 22.3
Other healthcare staff43431510.10.6 to to 29.2
History PCR and symptoms
Previous symptoms suggestive of SARS-CoV-2266a 732577728.721.7 to to 32.8
No previous symptoms suggestive of SARS-CoV-2601a 26555293.50.0 to to 5.7
Previous PCR nasopharyngeal swab for SARS-CoV-29939973838.527.7 to 50.626.60.0 to 43.4
No previous PCR nasopharyngeal swab for SARS-CoV-276960715688.03.1 to to 10.8
  • aOne patient did not have a valid option recorded. PCR = polymerase chain reaction.